Snowball logo
logo
ZVSA

ZyVersa Therapeutics Inc.

ZVSA • NASDAQ
$0.001$0.00  (0%)
Estimate
EPS
-2.79
Beta
0.845
About the company
Ticker
ZVSA
ISIN
US98987D3008
Country
United States of America
Sector (GICS)
Healthcare
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

Frequently asked questions

What sector does ZyVersa Therapeutics Inc. (ZVSA) operate in?

ZyVersa Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.

What is ZyVersa Therapeutics Inc. (ZVSA) current stock price?

As of the latest data, ZyVersa Therapeutics Inc. stock price is $0.00, with a previous close of $0.00.

What is ZyVersa Therapeutics Inc. (ZVSA) current market capitalization?

ZyVersa Therapeutics Inc. market cap is approximately 8.10 thousand.

What is ZyVersa Therapeutics Inc. (ZVSA) Earnings Per Share (EPS)?

The trailing EPS is -$2.79.

Does ZyVersa Therapeutics Inc. (ZVSA) pay dividends?

No. ZyVersa Therapeutics Inc. does not pay a dividend.

What is ZyVersa Therapeutics Inc. (ZVSA) beta (volatility) score?

ZyVersa Therapeutics Inc. has a beta of 0.845, meaning its volatility is roughly in line with the market.